Safety First Trust Series 2009-2 (ABI)

22.98
0.23 1.01
Prev Close 22.75
Open 22.98
Day Low/High 22.98 / 22.98
52 Wk Low/High 18.94 / 24.20
Volume 630.00
Exchange n.a.
Shares Outstanding 2.36M
Market Cap 54.32M
Div & Yield N.A. (N.A)

Latest News

Molson Coors Pushes to New Highs Despite Everyone Drinking Wine

Molson Coors Pushes to New Highs Despite Everyone Drinking Wine

It's about time we understood the enigma that is Molson Coors.

Corona Launches Global Partnership With SFX

Corona Launches Global Partnership With SFX

SFX Entertainment, Inc. (NASDAQ:SFXE) and  Anheuser-Busch InBev (Euronext:ABI) yesterday announced  Corona SunSets, a new music experience bringing together top DJs and rising stars in celebration...

Anheuser-Busch InBev Completes Acquisition Of Oriental Brewery

Anheuser-Busch InBev Completes Acquisition Of Oriental Brewery

Anheuser-Busch InBev (“AB InBev”) (Euronext: ABI) (NYSE: BUD), KKR and Affinity Equity Partners (“Affinity”) today announced that AB InBev has successfully completed the acquisition of Oriental Brewery...

Life Technologies Says Demand Held Up In 3Q

Life Technologies says 3Q sales edged up 3 percent after merger; raises full-year profit goal

Accuray Appoints 2 To Board

Accuray appoints 2 to board, including former Genentech executive

Will Someone, Anyone, Buy the Chicago Cubs?

Will Someone, Anyone, Buy the Chicago Cubs?

After two-plus years on the auction block -- and at least 10 serious bids -- the Chicago Cubs are about to be sold ... maybe. Could the deal be as cursed as the team?

Drinking With the Stars: Celebrity Booze

Drinking With the Stars: Celebrity Booze

Do you really wanna drink a beer endorsed by Kid Rock? Or, worse, a tequila with Sammy Hagar's face on it? It's time to reach for the hangover helper.

So Over It: Celebrity Booze

So Over It: Celebrity Booze

Do you really wanna drink a beer endorsed by Kid Rock? Or, worse, a tequila with Sammy Hagar's face on it? It's time to reach for the hangover helper.

Lampert Buys $4.7M Worth of AutoNation

Jonathan Moreland, author of InsiderInsights, gives you the lowdown on top stock purchases and sales.

Health Winners & Losers: Invitrogen

Invitrogen shares slide on news of a $6.7 billion deal to acquire Applera's Applied Biosystems.

Invitrogen, Applied Biosystems Ink Merger

The biotech will pay $38 a share, or about $6.7 billion, for the instruments company in a combination of cash and stock.

Stockpickr's Activist Track Stocks

Large shareholders are clamoring for change at these companies; their bets may be worth piggybacking.

Stockpickr's Activist Track Stocks

Large shareholders are clamoring for change at these companies; their investments may be worth piggybacking.

Garmin Shares Skid After TomTom Warning

Netherlands-based TomTom expects first-quarter revenue in a range of 270 million euros to 280 million euros.

Dykstra's Deep-in-the-Money Calls: Garmin

The GPS leader's October calls present a compelling trade.

The Real Winners of Drug Experimentation

The Real Winners of Drug Experimentation

The companies that supply the tools needed for pharma research and development often profit no matter the success of a drug trial.

Investor Worries About Garmin Might Be Overblown

A chipmaker's gloomy revenue forecast shouldn't affect Garmin, analysts say.

How Tainted Food Can Make You Money

These stocks will benefit from increased consumer concern about food safety.

Thursday's Health Winners & Losers

Gentium climbs on clinical trial news.

New Stock Favorites of Buffett, Soros and Icahn

Some of the newest stock holdings of the top traders.

Top Rocket Stocks for Week of Nov. 19

Dick's and H-P have the potential to move higher.

Thursday's Analysts' Upgrades and Downgrades

Who made what calls.

Wednesday's Health Winners & Losers

GlaxoSmithKline falls on disappointing quarterly results.

Friday's Health Winners & Losers

Celera climbs.

Celera, Merck Ink R&D Deal

The companies will develop companion tests for cancer therapies.

Enzo Biochem Falls on Court Dismissal

A district court grants Applied Biosystems' motion for a summary judgment in the patent-infringement case.

Friday's Health Winners & Losers

Pozen climbs on a reworked venture with AstraZeneca.

Checking Up on Biotech

Some highly focused health and biotech funds managed to perform well in recent volatility.